What barriers delay treatment in patients with hepatitis C?


Journal

The Journal of family practice
ISSN: 1533-7294
Titre abrégé: J Fam Pract
Pays: United States
ID NLM: 7502590

Informations de publication

Date de publication:
09 2022
Historique:
entrez: 30 9 2022
pubmed: 1 10 2022
medline: 5 10 2022
Statut: ppublish

Résumé

A Multiple patient-specific and provider-perceived factors delay initiation of treatment in patients with hepatitis C. Patient-specific barriers to initiation of treatment for hepatitis C virus (HCV) include age, race, gender, economic status, insurance status, and comorbidities such as HIV coinfection, psychiatric illness, and other psychosocial factors.Provider-perceived patient factors include substance abuse history, older age, psychiatric illness, medical comorbidities, treatment adverse effect risks, and factors that might limit adherence (eg, comprehension level).Study limitations included problems with generalizability of the populations studied and variability in reporting or interpreting data associated with substance or alcohol use disorders (strength of recommendation: B, based on 2 prospective and 5 retrospective cohort studies).

Identifiants

pubmed: 36179145
pii: jfp.0471
doi: 10.12788/jfp.0471
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E22-E24

Auteurs

Kimberly Crosby (K)

University of Oklahoma School of Community Medicine, Department of Family and Community Medicine, Tulsa.

Simone Bigelow (S)

University of Oklahoma School of Community Medicine, Department of Family and Community Medicine, Tulsa.

Viviane Sachs (V)

University of Oklahoma School of Community Medicine, Department of Family and Community Medicine, Tulsa.

Jennifer Weakley (J)

University of Oklahoma School of Community Medicine, Department of Family and Community Medicine, Tulsa.

Helga Skaftason (H)

University of Oklahoma School of Community Medicine, Department of Family and Community Medicine, Tulsa.

Toni Hoberecht (T)

University of Oklahoma- Tulsa, Schusterman Library.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH